GlassScriptPhysician profile
Emily A Phillips
NPI 1710497748
$6,201.10
in general payments reported to CMS, 2019-2025
33 companies · $44.99 in 2025
The $44.99 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,756 · 2022: $1,947 · 2023: $1,693 · 2024: $761 · 2025: $44.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.96 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $845.04 | 2021-2024 | Jardiance, Baqsimi, Mounjaro |
| Dexcom, INC. | $815.89 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $712.74 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $496.86 | 2021-2024 | Omnipod |
| Abbott Laboratories | $411.88 | 2021-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $351.47 | 2021-2023 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Amgen INC. | $254.47 | 2021-2024 | Repatha, Prolia, Evenity |
| Abbvie INC. | $237.03 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $225.95 | 2021-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $212.11 | 2021-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.47 | 2021-2024 | Jardiance |
| Corcept Therapeutics | $173.87 | 2021-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $163.45 | 2021-2023 | |
| Antares Pharma, INC. | $151.17 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Sanofi-Aventis U.S. LLC | $124.75 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $94.72 | 2021-2024 | Isturisa |
| Esperion Therapeutics, INC. | $84.46 | 2021-2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $78.63 | 2022-2023 | Strensiq |
| Amarin Pharma, INC. | $72.22 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $69.47 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $66.97 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Clarus Therapeutics INC. | $64.69 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $47.93 | 2022-2023 | |
| Zealand Pharma US, INC. | $45.02 | 2021-2022 | |
| Astellas Pharma US INC | $44.99 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.98 | 2021-2023 | Cycloset |
| Amryt Pharma Holdings LTD | $32.79 | 2022 | |
| Mannkind Corporation | $17.93 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.86 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.64 | 2021 | |
| Lifescan, INC. | $14.19 | 2021 | |
| Nevro Corp. | $13.23 | 2021 | |
| Eusa Pharma (US) LLC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.